1. New developments in the field of mastocytosis and mast cell activation syndromes: a summary of the Annual Meeting of the European Competence Network on Mastocytosis (ECNM) 2019
- Author
-
Jason Gotlib, Karin Hartmann, Cem Akin, Michel Arock, Peter Valent, Wolfgang R. Sperr, Karl Sotlar, Lawrence B. Schwartz, Hans-Peter Horny, Centre de Recherche des Cordeliers (CRC (UMR_S_1138 / U1138)), École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université Paris Cité (UPCité), Service d'Hématologie clinique [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Paracelsus Medizinische Privatuniversität = Paracelsus Medical University (PMU), Stanford Cancer Institute, Medizinische Universität Wien = Medical University of Vienna, University Hospital Basel [Basel], Virginia Commonwealth University (VCU), University of Michigan [Ann Arbor], University of Michigan System, Ludwig-Maximilians-Universität München (LMU), Arock, Michel, Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Université de Paris (UP), and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
Adult ,tyrosine-kinase inhibitors ,Cancer Research ,medicine.medical_specialty ,[SDV.IMM] Life Sciences [q-bio]/Immunology ,Hematologic Neoplasms ,Disease ,Article ,03 medical and health sciences ,0302 clinical medicine ,Mastocytosis, Systemic ,Bone Marrow ,MESH: Child ,Humans ,Medicine ,Mast Cells ,Systemic mastocytosis ,Child ,MESH: Mastocytosis, Systemic ,mastocytosis ,MESH: Humans ,business.industry ,Mast cell activation ,Network on ,scoring ,KIT ,MESH: Adult ,MESH: Mast Cells ,Hematology ,medicine.disease ,Dermatology ,3. Good health ,Europe ,medicine.anatomical_structure ,classification ,Oncology ,030220 oncology & carcinogenesis ,MESH: Mastocytosis ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,MESH: Bone Marrow ,MESH: Europe ,Bone marrow ,business ,030215 immunology - Abstract
International audience; Mastocytosis are a group of hematologic neoplasms characterized by an accumulation of atypical mast cells in one or several organs/tissues, often accompanied by mast cell activation. Whereas in children the disease manifestations are mostly limited to the skin, in adults the disease is usually systemic (systemic mastocytosis; SM) and involves the bone marrow and/or other internal organs. Several variants of SM have been defined. Whereas most patients have indolent SM, some patients have advanced SM, which underlines the complexity of SM. In 2002, a European consortium of clinicians and scientists initiated a multidisciplinary, multinational cooperative network, termed the 'European Competence Network on Mastocytosis' (ECNM), with the aim to improve diagnosis and therapy of patients with mastocytosis and other mast cell activation disorders. Since then, members of the ECNM have organized Annual Meetings in several European countries. The present article provides a summary of advances in the field presented during the 17th Annual ECNM meeting held in Salzburg in October 2019.
- Published
- 2019
- Full Text
- View/download PDF